Company intelligence / Profile preview

Belite Bio, Inc

San Diego, California, United Statesbelitebio.com ↗

Ownership: Public · BLTE
Employees: ~25
Development stage: Other

Overview

Belite Bio's lead candidate Tinlarebant (LBS-008) is in Phase 3 clinical trials for Stargardt disease and Geographic Atrophy. The company has completed a two-year Phase 2 study in adolescent STGD1 subjects. In February 2025, they announced interim analysis results from their pivotal global Phase 3 trial. Their DRAGON Phase 3 trial for STGD1 has completed enrollment with interim data expected in Q4 2024.

Therapeutic areas: OphthalmologyGastroenterologyEndocrinology
Modalities: Small moleculesOral therapies
Industry: Biotech

Drug pipeline

2 assets

tinlarebant

1 more asset in the full pipeline.

Financials

Market cap: $5.7B
Total revenue: $0
Enterprise value: $5.7B

Beyond the preview

Go deeper on Belite Bio, Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Belite Bio, Inc.